Trials / Recruiting
RecruitingNCT07284043
A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] MT1013/MT1013 Injection | \[14C\] MT1013/MT1013 Injection |
Timeline
- Start date
- 2025-11-30
- Primary completion
- 2026-11-01
- Completion
- 2027-03-01
- First posted
- 2025-12-16
- Last updated
- 2025-12-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07284043. Inclusion in this directory is not an endorsement.